You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新開源(300109.SZ):子公司擬與廣州威溶特醫藥科技設合資公司
格隆匯 11-22 19:43

格隆匯11月22日丨新開源(300109.SZ)公佈,公司於2022年11月20日召開第四屆董事會第四十七次會議審議並通過了《關於全資子公司擬參股設立合資公司的議案》,公司全資子公司上海新開源精準醫療有限公司(“上海新開源”)擬與廣州威溶特醫藥科技有限公司(“威溶特”)雙方共同投資1000萬元人民幣在上海市設立合資公司(“合資公司”)。上海新開源認繳註冊資本為人民幣600萬元,持股比例為60%;威溶特認繳註冊資本為人民幣400萬元,持股比例為40%。

威溶特作為乙方,其認繳的註冊資本應按照合資公司所在地工商登記機關的要求提交技術出資文件並予以登記備案,以ZAP及Mxra8兩項專有技術(專利)技術有條件全球獨家許可的形式實繳到位。

乙方將其正在研發的VRT501(ZAP蛋白測定試劑盒)及VRT502(Mxra8蛋白測定試劑盒)兩項專有技術(專利)全球獨家許可給合資公司,由合資公司負責相關產品的註冊及市場推廣。

若乙方將溶瘤病毒M1進行國際許可或轉讓時,若受讓方要求以上兩個伴隨診斷專有技術(專利)捆綁轉讓,則不受本協議中獨家許可權利的限制,即:乙方可以將以上兩個伴隨診斷專有技術(專利)捆綁轉讓,但同時乙方應保證甲方獲得不少於其為合資公司投入資金的補償。

此次設立合資公司旨在雙方優勢互補,互惠共贏,進一步整合各自的優勢資源,提升公司精準醫療板塊的發展水平。

此次合作有利於公司佈局未來在健康服務領域擁有全面、完整、極具競爭力的技術佈局。有利於公司發揮自身資金及技術能力,為合資公司提供全面運營、技術、供應鏈服務、項目融資和資本市場對接等支撐。對公司業務發展產生積極影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account